Breakthrough T1D

EN VIVO: Desgaste Emocional en Diabetes tipo 1 x.com/i/broadcasts/1…

We're making incredible progress towards transforming type 1 diabetes (T1D) every day. One of the companies on the cutting edge is @VertexPharma. They are currently investigating a cell therapy using manufactured islet cells in an ongoing Phase 1/2/3 clinical trial. We interviewed Vertex’s Joy L Silva, Senior Vice President, Disease Area Executive, Type 1 Diabetes, who has a personal connection to T1D—that is what drives her in her daily work. Learn more about Vertex’s role in advancing T1D research here: breakthrought1d.org/news-and-updat…

For families facing type 1 diabetes (T1D), new scientific advances bring meaningful hope. Annie, who lives with T1D, shares her story as a mother of a 7-year-old son who has T1D autoantibodies and, up until now, had no options for intervention. With the new @FDA approval of Tzield for children ages 1 and up, there is now a therapy that can delay the progression of T1D. This milestone represents a very significant step forward for families like Annie’s—offering more time without needing insulin, which means additional years without the physical, emotional, and financial burdens of this disease. We applaud the @FDA for this approval. This progress moves us closer to cures for T1D.

Today, @sanofi announced the U.S. Food and Drug Administration (@FDA) approved Tzield (teplizumab-mzwv) for use in children ages 1 and up in stage 2 type 1 diabetes (T1D). Breakthrough T1D thanks the FDA for this approval and Sanofi for their commitment to new therapies for the T1D community. Breakthrough T1D celebrates this decision which gives families with young children the ability to delay T1D onset, giving them additional years without the physical, emotional, and mental burdens of T1D. This decision highlights the urgent need for screening for T1D at every age – early detection is the only way take advantage of Tzield and delay progression of the disease. Read the link below to learn more about this approval and how to get screened for T1D. breakthrought1d.org/news-and-updat…

Breakthrough T1D Walk is a nationwide movement dedicated to raising type 1 diabetes (T1D) awareness and funding research. As the largest T1D walk, this event empowers individuals and teams to take action. But we couldn’t do it alone—our local volunteers make each event possible. Head to the link below to learn about Casey, the Corporate Committee Co-Chair for the Los Angeles Walk, and how his role helps us drive towards a world without T1D! bit.ly/4e1xhHS

Breakthrough T1D is heartbroken to learn of the passing of Madison Warner, daughter of U.S. Senator Mark Warner and Lisa Collis. Senator Warner has been a strong supporter of Breakthrough T1D and an advocate for the type 1 diabetes (T1D) community, as Madison lived with T1D. Our thoughts are with Senator Warner, his wife, Lisa, and the entire Warner family during this very difficult time. This is another tragic reminder that our work is not done. Breakthrough T1D will continue to fight tirelessly for cures so that no family has to experience the loss of a loved one to type 1 diabetes and its complications.

Happy #NationalVolunteerWeek from all of us to all of you! This week, Breakthrough T1D proudly celebrates the volunteers who are powering our movement. Thank you for all you do, we couldn’t do it without you! #PartneringforInnovation

🏃💨 Don't miss out on a weekend full of challenging runs and lightening fast gaming! All benefiting @BreakthroughT1D and #type1diabetes research 💙 📺 Hosted by @spikevegeta on twitch.tv/spikevegeta 📅 April 18 & 19 ➡️ More info at play.breakthrought1d.org/t1-dot-done/

This spring, bring your family, friends, and community together for a day of celebration, connection, and impact with Breakthrough T1D Walk. Whether you’ve joined before, or this is your first event, we’ll help you take the first step in joining our movement to transform life with T1D. Check out the locations already posted, find a fundraiser, and stay tuned for fall events to be added soon at the link below! bit.ly/418Rqnd

Thank you @DrMakaryFDA for recognizing the urgent need for type 1 diabetes (T1D) cures and treatments. Breakthrough T1D looks forward to continuing to work with @FDA to accelerate #T1D cures. To learn more about the exciting research Breakthrough T1D is funding, visit the link below. breakthrought1d.org/explore-resear…

For millions of Americans, access to affordable insulin is literally a matter of life and death. No one should be forced to ration lifesaving medication just to make ends meet. Today, I joined a bipartisan group of colleagues to introduce the INSULIN Act, which would cap the cost of insulin at $35 per month for those with commercial or employer-sponsored insurance and create a pilot program to provide insulin to uninsured patients at the same cost.

In the greatest country on Earth, those with Type 1 diabetes shouldn’t have to go bankrupt to afford the insulin medication they need. Today, I introduced bipartisan legislation to change that.

We applaud U.S. Senators @SenatorShaheen, @SenatorCollins, @SenatorWarnock, and John Kennedy for introducing the bipartisan INSULIN Act of 2026. One of our foundational beliefs is that everyone should have access to the insulin they need to survive. Our community has been raising their voices on this issue for years, engaging with Congress, employers, health insurance companies, and drug manufacturers. The INSULIN Act builds upon recent progress by capping out-of-pocket costs, eliminating utilization management barriers, increasing transparency in the insulin market, and promoting generic and biosimilar competition. It also strengthens support for uninsured individuals through state pilot programs and a national insulin resource center. We are proud to support this legislation and urge the Senate to move swiftly to advance it. Take action here: www2.breakthrought1d.org/site/Advocacy?… #Type1Diabetes #InsulinAccess #HealthPolicy #Bipartisan

Connor was diagnosed with type 1 diabetes (T1D) when he was 10 years old. For years, he regularly experienced episodes of severe hypoglycemia and hyperglycemia, making his T1D extremely difficult to manage. Connor is a participant in Dr. Piotr Witkowski’s University of Chicago clinical trial of Eledon’s tegoprubart, an immunotherapy that is safer and with milder side effects than standard immunosuppressants. As a result of this trial, Connor has been off of insulin therapy for over 3 months! Watch the entire conversation about this Breakthrough T1D-funded research here: youtu.be/mT-KLBKETAk

Passionate advocates from across the country have joined us in Washington, D.C., for Breakthrough T1D on the Hill (formerly Government Day) for four days of community building, briefings, volunteer recognition, and representing the type 1 diabetes (T1D) community on Capitol Hill. CEO Aaron Kowalski shared our State of the Foundation update, and we presented the Breakthrough T1D Mary Tyler Moore Award to Princess Padmaja Kumari Parmar of Udaipur, India, with Mary’s husband, Dr. S. Robert Levine honoring Mary’s legacy. It was a powerful evening! Princess Padmaja’s remarks inspired the room. Diagnosed at the age of 5, Princess Padmaja is turning her platform into action - raising awareness, challenging stigma, and advocating for people with T1D worldwide. Now, our advocates are taking their lived experiences to Capitol Hill, meeting with Members of Congress and calling for sustained Federal research funding, including the Special Diabetes Program that helps power T1D breakthroughs. Learn more here: bit.ly/479bZE1 #GovDay2026

Exciting University of Chicago clinical trial update testing Eledon's tegoprubart. Today, we take you behind the breakthroughs with a conversation between Piotr Witkowski, M.D., Ph.D. and Breakthrough T1D CEO Aaron J. Kowalski, Ph.D. as they discuss progress on this Breakthrough T1D-funded clinical trial investigating the use of tegoprubart with deceased donor islet cell transplants. The early results are exciting! Click here see their full conversation: youtube.com/watch?v=9y2mND…

Our team of scientific and medical experts just returned from the 2026 Advanced Technologies and Treatments for Diabetes (ATTD) conference. Partner- and Breakthrough T1D-funded research, clinical trials, screening and treatment program progress were all showcased throughout the event. Read all of the details here - bit.ly/3NJh7bf

EN VIVO: Diabetes Tipo 1 y Salud Femenina: Un Enfoque Integral para Cada Etapa de la Vida x.com/i/broadcasts/1…

Breakthrough T1D CEO Aaron Kowalski, Ph.D., sits down for a conversation with Katie Beth Hand, a participant in the University of Chicago's clinical trial testing Eledon's tegoprubart. Tegoprubart is used as an alternative to standard immunosuppressants to help prevent transplanted islet cells from rejection in people with type 1 diabetes. Watch their full conversation about this exciting Breakthrough T1D-funded clinical trial here: youtu.be/DBPovg84Lws